Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19 | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study2024
2Pharmacokinetics of Nirmatrelvir/Ritonavir after Multiple Administration in a Phase 1, Open-Label Study in Healthy Chinese Adults and Compared with Non-Chinese Participantsother · 2026
3Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in ChinaRetrospective Study · 2023 · 10 citations
4Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate <scp>COVID</scp> ‐19 and Severe Renal ImpairmentEarly-Phase Clinical Trial · 2026
5Patient-Reported Outcomes of Nirmatrelvir Treatment for High-Risk, Nonhospitalized Adults With Symptomatic COVID-192025 · 4 citations

More from Fundamental and Clinical Pharmacology

More from Shanghai Jiao Tong University